CA-VISA-INC
Visa (NYSE: V), a leading global payments technology company, announced today the formation of an Advisory Council for the Visa Economic Empowerment Institute. The Visa Economic Empowerment Institute is a forum for original research and public-private dialogue on payments and public policy. The Advisory Council will bring to the Institute decades of collective insights and experiences from some of the leading thought leaders in international finance and diplomacy in the world today. With the strategic guidance of the Advisory Council, the Visa Economic Empowerment Institute will be able to accelerate its agenda for driving access to digital payments and unlocking new opportunities for economic growth.
The founding members of the Visa Economic Empowerment Institute Advisory Council are:
- Dr. Axel Weber (Chair), former UBS Chairman and former president of the German Central Bank (Bundesbank). Weber is currently a senior global adviser to Boston Consulting Group and a member of the advisory board for fintech provider Raisin. “I am honored to serve as Chair of the inaugural Visa Economic empowerment Institute Advisory Council,” said Weber. “We need to overcome the continued gaps in economic opportunities that are making it difficult for all individuals to equally take part in the global payments ecosystem. I am confident that our collective knowledge and expertise at the Visa Economic Empowerment Institute will help drive impactful strides in public policies designed to empower all.”
- The Rt Hon. Lord Hill, Member of the House of Lords in the United Kingdom and former European Commissioner for Financial Stability, Financial Services and Capital Markets Union. “The biggest policy challenge we face in Europe is how to increase the competitiveness of our economy and accelerate growth. If we fail in that, we will fail in everything. Through its research, I hope the Visa Economic Empowerment Institute will help show policy makers what they need to do to strengthen their economies and spread opportunities for businesses to grow,” said Lord Hill.
- Ambassador Koji Tsuruoka, former Japanese Ambassador to the United Kingdom and chief negotiator for international trade agreements including the Trans-Pacific Partnership. Tsuruoka spent 43 years with Japan’s Ministry of Foreign Affairs. “I know firsthand the impact that strategic and international collaboration can have on expanding access to the global economy,” said Tsuruoka. “To be a part of the Visa Economic Empowerment Institute Advisory Council at its genesis is an exciting next chapter to unlock the potential and growth in payments.”
“The Visa Economic Empowerment Institute is a natural extension of Visa’s purpose – to uplift everyone, everywhere. Axel, Koji and Jonathan share our passion for economic empowerment and will bring new perspectives to the payments policy discourse,” said Kelly Mahon Tullier, Vice Chair, Chief People and Corporate Affairs Officer of Visa. “We are thrilled to add the strategic guidance of three global leaders whose collective expertise spans almost a century of knowledge.”
The Advisory Council will focus on amplifying the Visa Economic Empowerment Institute’s three strategic research pillars:
- Imagining an open future for payments: We identify opportunities for the public and private sectors to work together to create and sustain an open and innovative payments ecosystem so that individuals, businesses, and economies can thrive.
- Unlocking growth through trade: Working together, stakeholders can find the right balance to ensure that the digital trade realm is competitive, seamless, secure, and accessible to all.
- Fostering digital equity & inclusion: Our goal in promoting digital equity is to reach the point at which all individuals and businesses can participate in and receive the benefits of the digital economy.
For more information on the Visa Economic Empowerment Institute and Visa’s commitment to economic empowerment, visit here.
About Visa Inc.
Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231011135398/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom